Trial Profile
Efficacy of Adalimumab (Humira) in Spondyloarthritis Related to Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease; Spondylarthritis
- Focus Biomarker; Therapeutic Use
- 01 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 Oct 2009 New trial record